DMDongxu Ma

Dongxu Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dongxu Ma has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Heng Cao

    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    4 shared publications
  • Xiang Wang

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    4 shared publications
  • Hengyi Xu

    State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    3 shared publications
  • Jiang Wu

    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, cacms.ac.cn

    3 shared publications
  • Jiaqi Liu

    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    3 shared publications
  • Ziqi Jia

    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    3 shared publications

Latest Publications

  • Open Access

    Mitochondria Pathway Signature Predicts Prognosis and Therapeutic Response and Identifies REXO2 as a Crucial Regulator in Breast Cancer

    by Zizhao Guo, Heng Cao, Chuqi Lei, Dongxu Ma, Jiang Wu, Zeyu Xing, Chenyu Zhao, Xiang Wang, Jianxiu Cui

    Background: Mitochondrial‐related pathways (MRPs) play a crucial role in cancer metabolism and progression; however, their prognostic value in breast cancer (BC) is still poorly understood. Methods: We integrated multiomics data to investigate the landscape of MRPs in BC. A mitochondria pathways‐associated signature (MPAS) was established using multimachine learning framework and interpreted by SHAP analysis across independent BC cohorts. Additionally, a series of functional experiments were employed to explore the role of RNA exonuclease 2 (REXO2) in BC cells. Results: MRPs are extensively activated in BC at multiomics level. MPAS demonstrates outstanding predictive performance across multiple BC cohorts, with high scores indicating poor clinical outcomes. Moreover, it was observed that high MPAS scores are closely associated with immunosuppressive states and inflammatory microenvironments. SHAP analysis identified REXO2 as a hub factor of MPAS. Cell‐based work confirmed that silencing REXO2 greatly inhibited cell proliferation and induced apoptosis in BC. Conclusions: Our proposed MPAS could effectively evaluate the prognosis and treatment response of BC patients, providing new reference for clinical decision‐making. Furthermore, REXO2 regulates cell proliferation and apoptosis, making it a promising potential therapeutic target for inhibiting BC progression.

  • Open Access

    Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

    by Jiaqi Liu, Yalun Li, Wanxiangfu Tang, Tianyi Qian, Lijun Dai, Ziqi Jia, Heng Cao, Chenghao Li, Yuchen Liu, Yansong Huang, et al.

    The fragmentomics-based cell-free DNA (cfDNA) assays have recently illustrated prominent abilities to identify various cancers from non-conditional healthy controls, while their accuracy for identifying early-stage cancers from benign lesions with inconclusive imaging results remains uncertain. Especially for breast cancer, current imaging-based screening methods suffer from high false positive rates for women with breast nodules, leading to unnecessary biopsies, which add to discomfort and healthcare burden. Here, we enrolled 613 female participants in this multi-center study and demonstrated that cfDNA fragmentomics (cfFrag) is a robust non-invasive biomarker for breast cancer using whole-genome sequencing. Among the multimodal cfFrag profiles, the fragment size ratio (FSR), fragment size distribution (FSD), and copy number variation (CNV) show more distinguishing ability than Griffin, motif breakpoint (MBP), and neomer. The cfFrag model using the optimal three fragmentomics features discriminated early-stage breast cancer from benign nodules, even at a low sequencing depth (3×). Notably, it demonstrated a specificity of 94.1% in asymptomatic healthy women at a 90% sensitivity for breast cancer. Moreover, we comprehensively showcased the clinical utility of the cfFrag model in predicting patient responses to neoadjuvant chemotherapy (NAC) and its enhanced performance when combined with multimodal features, including radiological results [area under the curve (AUC) = 0.93–0.94] and cfDNA methylation features (AUC = 0.96).


  • Top Cited Papers
    Open Access

    Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance

    by Tongxuan Shang, Ziqi Jia, Jiayi Li, Heng Cao, Hengyi Xu, Lin Cong, Dongxu Ma, Xiang Wang, Jiaqi Liu

    In the domain of addressing cancer resistance, challenges such as limited effectiveness and treatment resistance remain persistent. Hypoxia is a key feature of solid tumors and is strongly associated with poor prognosis in cancer patients. Another significant portion of the development of acquired drug resistance is attributed to tumor stemness. Cancer stem cells (CSCs), a small tumor cell subset with self-renewal and proliferative abilities, are crucial for tumor initiation, metastasis, and intra-tumoral heterogeneity. Studies have shown a significant association between hypoxia and CSCs in the context of tumor resistance. Recent studies reveal a strong link between hypoxia and tumor stemness, which together promote tumor survival and progression during treatment. This review elucidates the interplay between hypoxia and CSCs, as well as their correlation with resistance to therapeutic drugs. Targeting pivotal genes associated with hypoxia and stemness holds promise for the development of novel therapeutics to combat tumor resistance.


  • Open Access

    Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

    by Jiaqi Liu, Yalun Li, Wanxiangfu Tang, Lijun Dai, Ziqi Jia, Heng Cao, Chenghao Li, Yuchen Liu, Yansong Huang, Jiang Wu, et al.

    The fragmentomics-based cell-free DNA (cfDNA) assays have recently illustrated prominent abilities to identify various cancers from non-conditional healthy controls, while their accuracy for identifying early-stage cancers from benign lesions with inconclusive imaging results remains uncertain. Especially for breast cancer, current imaging-based screening methods suffer from high false-positive rates for women with breast nodules, leading to unnecessary biopsies, which add to discomfort and healthcare burden. Here, we enroll 560 female participants in this multi-center study and demonstrate that cfDNA fragmentomics is a robust non-invasive biomarker for breast cancer using whole-genome sequencing. Among the multimodal cfDNA fragmentomics profiles, the fragment size ratio (FSR), fragment size distribution (FSD), and copy number variation (CNV) show more distinguishing ability than Griffin, motif breakpoint (MBP), and neomer. The cfDNA fragmentomics (cfFrag) model using the optimal three fragmentomics features discriminated early-stage breast cancers from benign nodules, even at a low sequencing depth (3×). Notably, it demonstrated a specificity of 94.1% in asymptomatic healthy women at a 90% sensitivity for breast cancers. Moreover, we comprehensively showcase the clinical utilities of the cfFrag model in predicting patient responses to neoadjuvant chemotherapy (NAC) and in combining with multimodal features, including radiological results and cfDNA methylation features (with AUC values of 0.93 – 0.94 and 0.96, respectively).